Why Intellia Therapeutics (NTLA) Is Up 14.2% After FDA Lifts MAGNITUDE Trial Holds and Upgrade
Intellia Therapeutics (NTLA) shares rose 14.2% after the FDA lifted clinical holds on its MAGNITUDE and MAGNITUDE-2 ATTR trials, providing renewed regulatory clarity. This decision followed an upgrade from Jones Trading and has positively impacted Intellia's investment narrative, particularly concerning its CRISPR pipeline's resilience. The company now looks forward to key HAELO Phase 3 data, reinforcing the potential for its one-time CRISPR interventions, despite ongoing concerns about long-term safety and commercial viability.
Intellia Therapeutics Announces Inducement Grants
Intellia Therapeutics has awarded inducement grants consisting of 67,150 shares of common stock in time-based restricted stock units (RSUs) to 13 new employees. These grants, made under the company's 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), are designed to attract and retain top talent in the biopharmaceutical industry. The RSUs will vest annually over a three-year period, demonstrating Intellia's commitment to expanding its workforce and advancing its CRISPR-based gene-editing therapies.
Intellia Grants 67,150 RSUs to 13 New Hires
Intellia Therapeutics announced it has awarded 67,150 time-based Restricted Stock Units (RSUs) to 13 new employees as a material inducement for their employment. These grants, vesting over three years, are part of the biopharmaceutical company's strategy to attract and retain top talent in the competitive gene editing industry. This move underscores Intellia's commitment to advancing its CRISPR-based therapies and building a strong team to achieve its goals.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics announced it awarded inducement grants to 13 new employees on April 1, 2026, consisting of 67,150 restricted stock units (RSUs). These grants, vesting over three years, were made under Intellia’s 2024 Inducement Plan as a material inducement for employment and comply with Nasdaq Listing Rule 5635(c)(4). Intellia Therapeutics is a biopharmaceutical company focused on CRISPR gene editing treatments.
13 new Intellia employees get 67,150 stock units over 3 years
Intellia Therapeutics (Nasdaq: NTLA) announced it granted inducement awards of 67,150 Restricted Stock Units (RSUs) to 13 new employees on April 1, 2026. These RSUs will vest one-third annually over three years, contingent on continued service, and were approved under Nasdaq Listing Rule 5635(c)(4). The grants were made outside stockholder-approved plans and are a standard practice for attracting new talent.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. announced that it granted inducement awards to 13 new employees on April 1, 2026, consisting of 67,150 time-based restricted stock units. These grants were made under Intellia’s 2024 Inducement Plan as a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest annually over three years, contingent on continued service.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Hold" from Brokerages
Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received a consensus "Hold" rating from twenty brokerages, with an average 12-month price target of $19.59. Despite the company beating EPS and revenue estimates in its latest quarter, it remains unprofitable, with analysts forecasting a negative EPS for the current year. Insider selling occurred last quarter, while institutional investors hold a significant majority of the stock.
Trending Industry Today: Intellia Therapeutics Leads Losses In Gene Editing Stocks
This article reports on the trending gene editing industry, highlighting that Intellia Therapeutics is leading the losses among gene editing stocks. The content indicates a negative trend within this specific sector.
Intellia Therapeutics (NTLA) — Vanguard disaggregates holdings, parent reports 0 shares
The Vanguard Group has filed an amended Schedule 13G/A for Intellia Therapeutics (NTLA), reporting 0 shares and 0% beneficial ownership. This change is due to an internal realignment that disaggregates holdings to its subsidiaries, meaning Vanguard itself no longer formally beneficially owns these securities. The filing indicates that subsidiaries will now report their ownership separately, affecting only the reporting structure, not the underlying investment strategy.
Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Strong-Buy at Truist Financial
Truist Financial has upgraded Intellia Therapeutics (NASDAQ:NTLA) to a "strong-buy" rating. Despite this, the MarketBeat consensus remains a "Hold" with a $19.59 price target. The company recently exceeded quarterly earnings and revenue expectations, but some insiders have sold shares.
Investors in Intellia Therapeutics, Inc. Should Contact Levi & Ko
Levi & Korsinsky LLP is urging investors in Intellia Therapeutics, Inc. (NASDAQ: NTLA) who suffered losses between July 30, 2024, and January 8, 2025, to contact them regarding a potential securities class action lawsuit. The lawsuit alleges that Intellia failed to disclose that its NTLA-3001 program was becoming inefficient due to the rise of non-viral delivery methods, leading to a significant stock drop after the company announced a reorganization and workforce reduction. Investors have until April 14, 2025, to discuss their rights.
Hudson Bay Capital Management LP Sells 235,000 Shares of Intellia Therapeutics, Inc. $NTLA
Hudson Bay Capital Management LP significantly reduced its stake in Intellia Therapeutics (NASDAQ:NTLA) by 50.5%, selling 235,000 shares and retaining 230,000 shares valued at approximately $3.97 million. Company insiders also sold over 53,000 shares in the last 90 days. Despite the institutional sell-off, Intellia Therapeutics exceeded Q3 revenue and EPS estimates, though it remains unprofitable, with analysts holding a consensus "Hold" rating and an average price target of $19.59.
How Intellia Therapeutics Inc. (NTLA) Affects Rotational Strategy Timing
The article analyzes Intellia Therapeutics Inc. (NTLA) using AI models, identifying a positive near-term sentiment while a mid-term weak bias exists within a long-term strength context. It highlights an exceptional 112.5:1 risk-reward short setup and provides institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging. Multi-timeframe signal analysis offers insights into support and resistance levels across different horizons.
Farallon Capital Management LLC Purchases Shares of 607,200 Intellia Therapeutics, Inc. $NTLA
Farallon Capital Management LLC has acquired a new position of 607,200 shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA), valued at approximately $10.486 million, representing about 0.52% of the company's stock. Other institutional investors also increased their holdings, while company insiders sold shares totaling over $488,000 in the last ninety days. Intellia Therapeutics, a clinical-stage biotechnology company focused on CRISPR/Cas9 genome editing therapies, recently reported better-than-expected earnings, exceeding analyst revenue estimates.
Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing?
Intellia Therapeutics has reported positive long-term data for its CRISPR-based HAE candidate lonvoguran ziclumeran and received FDA clearance to resume Phase 3 testing for its ATTR-CM therapy nexiguran ziclumeran. These developments highlight the potential of one-time in vivo gene-editing treatments as alternatives to chronic therapies and shift the investment focus from regulatory uncertainty to execution risk in late-stage trials. Despite recent positive news, the company still faces ongoing losses, tighter liver safety scrutiny, and long timelines to profitability, which are important considerations for investors.
Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing?
Intellia Therapeutics has reported positive long-term data for its HAE candidate and regained FDA clearance for its ATTR-CM therapy, highlighting its effort to establish gene-editing treatments as alternatives to chronic therapies. These developments reinforce the company's investment narrative focused on the commercial viability of in vivo CRISPR, shifting investor attention from regulatory uncertainty to execution risk in late-stage trials. Despite recent progress and a recovering share price, investors need to consider ongoing losses, tight liver safety scrutiny, and long timelines to profitability.
Leerink Global Healthcare Conference - Intellia Therapeutics
Intellia Therapeutics is scheduled to participate in the Leerink Global Healthcare Conference on March 9, 2026, at 8:40 AM EDT in Miami, FL. The event will include a webcast, and details are available on the company's investor relations page.
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Hold Lift And New Gene Editing Data
Intellia Therapeutics has seen its stock performance improve significantly following the FDA lifting a clinical hold on its MAGNITUDE Phase 3 trial and promising new data for its hereditary angioedema gene editing therapy, lonvoguran ziclumeran. Despite recent gains, analysis suggests NTLA is currently undervalued, with a fair value estimate of $23.86 compared to its current trading price of $13.44, predicated on strong long-term growth and market expansion assumptions. Investors are encouraged to review the underlying financial data and potential risks, such as clinical setbacks or slower therapy adoption, which could impact future performance.
Cathie Wood's Intellia Therapeutics Surges 47%: Is It Too Late to Invest?
Intellia Therapeutics has seen a 47% surge in its stock price this year, driven by the FDA lifting clinical holds on its gene-editing drug nex-z for hereditary angioedema. While this development has boosted investor confidence and offers potential new revenue streams, the company still faces risks related to unclarified safety concerns and the high costs and complexities of gene-editing therapies. Analysts have mixed views, with some upgrading the stock due to regulatory clarity, while others maintain a neutral stance despite increased price targets.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. announced inducement grants to six new employees on March 1, 2026, consisting of 16,500 restricted stock units (RSUs) vesting over three years. These grants were made under Intellia's 2024 Inducement Plan as a material inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The company is a clinical-stage biopharmaceutical firm focused on CRISPR gene editing to treat severe diseases.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. announced that it awarded inducement grants to six new employees on March 1, 2026, under its 2024 Inducement Plan. These grants consisted of time-based restricted stock units for an aggregate of 16,500 shares, vesting annually over three years, and were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The company is a clinical-stage biopharmaceutical leader focused on CRISPR gene editing.
Is Intellia Therapeutics (NTLA) Pricing Look Interesting After Strong Year-To-Date Share Gain?
Intellia Therapeutics (NTLA) has seen significant share gains recently, prompting analysis into its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is heavily undervalued by 91.0%, indicating an intrinsic value of US$153.09 per share compared to its recent price of US$13.82. However, its Price-to-Sales (P/S) ratio of 24.13x appears expensive when compared to its estimated "Fair Ratio" of 0.07x and the biotech industry average, suggesting it might be overvalued by this metric. Investors are encouraged to create personalized "Narratives" on Simply Wall St to combine their expectations with financial forecasts for a comprehensive valuation.
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial
The FDA has issued 30 warning letters to telehealth companies for making false claims about compounded GLP-1 products, marking its second round of such actions. Separately, Intellia Therapeutics received clearance to resume a Phase 3 trial for a heart condition, having implemented new safeguards after a participant's death. Furthermore, United Therapeutics' pulmonary arterial hypertension drug, ralinepag, surpassed expectations in a Phase 3 trial, and Merck detailed positive study results for its kidney cancer drug, Welireg.
Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial
Intellia Therapeutics (NASDAQ: NTLA) shares rose following the FDA's decision to lift the clinical hold on its MAGNITUDE Phase 3 trial, which evaluates nexiguran ziclumeran for transthyretin amyloidosis with cardiomyopathy. The hold was initially imposed in October 2025 due to a patient experiencing Grade 4 liver transaminases and increased bilirubin. The company has aligned with the FDA on mitigation measures, including enhanced monitoring and revised exclusion criteria, positioning the stock with a "Buy" rating and an average price target of $19.73 from analysts.
Intellia Therapeutics Presents Longer-Term Clinical Data
Intellia Therapeutics presented longer-term clinical data for its investigational drug lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) at the AAAAI 2026 meeting. The presentations highlighted three-year follow-up data showing deep, stable, and durable reductions in plasma kallikrein and HAE attacks with a one-time 50 mg dose of lonvo-z. The company also presented survey findings underscoring the ongoing burden and unmet needs for HAE patients, positioning lonvo-z as a potential first one-time treatment for the condition.
Intellia Therapeutics (NTLA) CMO awarded options and RSUs in Form 4 filing
Intellia Therapeutics' Executive Vice President and Chief Medical Officer, David Lebwohl, reported equity awards in a recent Form 4 filing. He received 14,204 stock options and 9,943 restricted stock units (RSUs) on March 1, 2026, increasing his direct ownership in the company to 131,192 shares of Common Stock. The stock options have an exercise price of $0.00 and RSU shares were also acquired at $0.00, with specific vesting schedules detailed for the options.
Vanguard Group Inc. Acquires 192,651 Shares of Intellia Therapeutics, Inc. $NTLA
Vanguard Group Inc. increased its stake in Intellia Therapeutics, Inc. by 1.8% in the third quarter, acquiring an additional 192,651 shares. This brings Vanguard's total holdings to 11,044,820 shares, representing approximately 10.29% of Intellia Therapeutics, valued at $190.7 million. The article also notes recent positive clinical news for Intellia and highlights varied analyst ratings, with an average "Hold" and a consensus price target of $18.50.
Intellia Therapeutics, Inc. $NTLA is Contrarius Group Holdings Ltd's 6th Largest Position
Contrarius Group Holdings Ltd significantly increased its stake in Intellia Therapeutics (NTLA) by 279.4% in Q3 2025, making it the fund's sixth-largest holding. This comes as the FDA lifted a clinical hold on Intellia's MAGNITUDE Phase 3 IND for nexiguran ziclumeran, and the company completed enrollment for another Phase 3 trial. Despite regulatory progress and analyst upgrades, Intellia remains a pre-revenue company with negative margins, and recent insider sales have occurred.
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
Intellia Therapeutics presented longer-term clinical data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) at AAAAI 2026, showing a 96% mean reduction in HAE attacks and 97% of patients attack-free/LTP-free after a single 50 mg dose through up to three years. The data highlights the significant efficacy and durability of lonvo-z, contrasting with a patient survey that underscored ongoing treatment burden with existing chronic therapies. This information, released alongside recent FDA clinical hold removals for other Intellia programs, suggests continued progress in the company's gene-editing pipeline for severe diseases.
Intellia Therapeutics Shares Surge Amid Steller Earnings and Promising CRISPR Advances
Intellia Therapeutics stock surged over 10% after the company reported better-than-expected Q4 earnings, with revenue significantly exceeding analyst expectations and a narrower net loss. Investor confidence was further boosted by rapid progress in multiple Phase 3 CRISPR-based programs and an anticipated BLA submission in 2026 for a key therapy. Analysts have upgraded price targets, reflecting a positive outlook on the company's trajectory and its strategic talent acquisition efforts.
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 10.7% on Analyst Upgrade
Intellia Therapeutics (NASDAQ:NTLA) saw its stock price jump 10.7% after William Blair upgraded its rating to "outperform." The company recently reported better-than-expected quarterly earnings and revenue, though it remains unprofitable. Analyst opinions on the stock are currently divided, with a consensus "Hold" rating but a wide range of price targets.
Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial
Intellia Therapeutics (NASDAQ: NTLA) shares rose following the FDA's decision to lift the clinical hold on its MAGNITUDE Phase 3 clinical trial, which evaluates nexiguran ziclumeran for transthyretin amyloidosis with cardiomyopathy. The hold was initially imposed due to observed Grade 4 liver transaminases and increased bilirubin in a patient. The company has aligned with the FDA on mitigation measures including enhanced liver monitoring and patient exclusion criteria.
Intellia Therapeutics Inc - Increases At-The-Market Offering Program To $1.04 Billion- SEC Filing
Intellia Therapeutics Inc. (NTLA) has increased its At-The-Market (ATM) offering program to $1.04 billion, as disclosed in an SEC filing. This update, reported by Refinitiv/Reuters, indicates a significant change in the company's financial strategy regarding its equity offerings. The news is categorized under strategy, business, and US stocks.
FDA Lifts Hold on Intellia Therapeutics' (NTLA) Phase 3 Trial
The FDA has lifted the clinical hold on Intellia Therapeutics' MAGNITUDE Phase 3 trial for transthyretin amyloidosis with cardiomyopathy, allowing it to resume after new mitigation strategies were established for liver safety concerns. While this is a significant step for the gene-editing company, Intellia Therapeutics (NTLA) faces financial challenges, including negative margins and high valuation but strong liquidity.
FDA ends trial halt on 1,200-patient heart disease study
Intellia Therapeutics announced that the FDA has lifted the clinical hold on the Investigational New Drug (IND) for its MAGNITUDE Phase 3 trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The hold, imposed due to a severe liver event, was lifted after Intellia and the FDA agreed on enhanced safety measures including intensified liver monitoring and new exclusion criteria. This resolution, combined with the earlier lift of the hold on the MAGNITUDE-2 trial, allows enrollment to resume for both studies.
Intellia gets FDA nod to resume second gene therapy trial after safety pause
The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Intellia Therapeutics' late-stage gene therapy trial for a heart disease, sending the company's shares up 2%. The trial for nexiguran ziclumeran, which treats transthyretin amyloidosis, was paused last year after a patient's death due to severe liver complications. Intellia has implemented mitigation measures, including enhanced liver monitoring and new patient exclusion criteria, to address safety concerns.
Intellia Therapeutics Inc increases at-the-market offering program to $1.04 billion - SEC filing
Intellia Therapeutics Inc. has increased its at-the-market offering program to $1.04 billion, according to an SEC filing. This news comes shortly after the U.S. FDA removed a clinical hold on the Magnitude Phase 3 trial for Nexiguran Ziclumeran, prompting a pre-market jump in Intellia's shares. The company develops genome editing therapeutics using CRISPR/Cas9 technology, with lead candidates for transthyretin amyloidosis and hereditary angioedema.
Intellia Therapeutics to Participate in Upcoming Investor Conferences
Intellia Therapeutics, a clinical-stage gene editing company, announced its participation in three upcoming investor conferences in March 2026. Management will hold fireside chats at the TD Cowen 46th Annual Health Care Conference and the Leerink Global Healthcare Conference, with webcasts available for live viewing and replays. They will also attend the Barclays 28th Annual Global Healthcare Conference.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)
Healthcare sector analysts have differing opinions on Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA). Needham maintained a Buy rating for Collegium Pharmaceutical with a $54.00 price target, leading to a "Strong Buy" consensus. Conversely, William Blair issued a Hold rating for Intellia Therapeutics, resulting in a "Moderate Buy" consensus with a $16.38 price target.
Intellia Therapeutics Q4 Loss Of US$0.83 EPS Tests Long Term Bullish Narratives
Intellia Therapeutics reported a Q4 2025 loss of US$0.83 EPS and a net loss of US$412.7 million for FY 2025, continuing heavy investment in its gene editing pipeline. While revenue is growing, profitability is not expected within the next three years, raising questions about its high 24.4x Price/Sales multiple compared to the biotech industry average. Despite ongoing losses, analyst targets and DCF fair value estimates remain significantly above the current share price due to strong projected revenue growth expectations.
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Intellia Therapeutics reported a narrower-than-expected Q4 2025 loss of 83 cents per share and total revenues of $23 million, beating analyst estimates. This performance led to a 6.4% rise in shares and follows sustained growth in collaboration revenues and strategic pipeline advancements. The company plans to fund operations into the second half of 2027, focusing on its lonvo-z candidate for hereditary angioedema with an anticipated launch in early 2027.
Intellia Therapeutics (NASDAQ:NTLA) Given "Buy" Rating at Chardan Capital
Chardan Capital has reissued a "Buy" rating for Intellia Therapeutics (NASDAQ:NTLA) with a price target of $26, suggesting an 82% upside. This comes after the company reported better-than-expected Q4 results for 2025 and saw the FDA lift a clinical hold on its MAGNITUDE-2 trial. However, the company remains loss-making with negative margins, and its stock has received a consensus "Hold" rating from analysts with an average price target of $17.48.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2025 Earnings Call Transcript
Intellia Therapeutics (NASDAQ: NTLA) discussed its Q4 2025 earnings and provided updates on its CRISPR gene-editing programs, lonvo-z for hereditary angioedema (HAE) and nex-z for ATTR amyloidosis. The company highlighted the rapid enrollment of its Phase 3 HAELO trial for lonvo-z, with top-line data expected by mid-2026 and a BLA submission in the second half of the year. For nex-z, the clinical hold on the polyneuropathy study (MAGNITUDE-2) was lifted by the FDA, with enrollment expected to complete by year-end, while engagement with the FDA for the cardiomyopathy study (MAGNITUDE) is ongoing regarding liver enzyme elevation concerns.
Intellia Therapeutics Inc (NASDAQ:NTLA) Reports Strong Q4 2025 Revenue Beat and Confirms Key 2026 Pipeline Milestones
Intellia Therapeutics Inc (NASDAQ:NTLA) announced strong Q4 2025 financial results, beating revenue estimates by approximately $10 million and reporting a narrower-than-expected loss per share. The company also confirmed key pipeline milestones for its lead hereditary angioedema (HAE) candidate, NTLA-2002, with Phase 3 data expected by mid-2026 and a U.S. launch anticipated in early 2027. This positive news led to a 4.7% surge in pre-market trading, signaling investor confidence in its financial performance and CRISPR-based therapy development.
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics announced its fourth quarter and full-year 2025 financial results and provided key business updates. The company ended 2025 with $605 million in cash, expecting to fund operations into the second half of 2027, and anticipates significant milestones in 2026, including Phase 3 clinical data for lonvo-z and a planned Biologics License Application submission. Intellia is also working to reactivate and resolve clinical holds on its nex-z Phase 3 trials for ATTR amyloidosis.
A Look At Intellia Therapeutics (NTLA) Valuation After Earnings Beat Trial Progress And FDA Hold Lift
Intellia Therapeutics (NTLA) saw its Q4 2025 results exceed expectations, with positive trial data for hereditary angioedema and an FDA clinical hold lifted on a partnered gene editing drug. Despite a significant 90-day share price rebound, its three-year return is down 69.49%, indicating recent positive momentum. Analysts are split on the valuation, with one narrative suggesting it's 92.3% undervalued based on potential phase 3 success and revenue projections, while another views its current 27x sales multiple as rich compared to industry averages.
Intellia Therapeutics Inc earnings beat by $0.13, revenue topped estimates
Intellia Therapeutics Inc (NASDAQ: NTLA) reported stronger-than-expected fourth-quarter results, with EPS beating analyst estimates by $0.13 and revenue significantly surpassing consensus. The company's stock has seen substantial gains over the last year, reflecting a "fair performance" financial health score according to InvestingPro.
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics reported its fourth quarter and full-year 2025 financial results, highlighting key business updates for its clinical programs. The company expects HAELO Phase 3 clinical data for lonvo-z in HAE by mid-2026 and plans a BLA submission in the second half of 2026. Additionally, Intellia is reactivating global sites for the MAGNITUDE-2 Phase 3 trial for nex-z in ATTRv-PN following the lifting of a clinical hold, and is engaging with the FDA regarding the MAGNITUDE Phase 3 trial for nex-z in ATTR-CM.
A Look At Intellia Therapeutics (NTLA) Valuation After Earnings Beat Trial Progress And FDA Hold Lift
Intellia Therapeutics (NTLA) has shown positive momentum with a Q4 2025 earnings beat, encouraging hereditary angioedema trial data, and the lifting of an FDA clinical hold. Despite recent share price gains, the stock's three-year return is down, and valuation narratives are split between significant undervaluation based on future revenue potential and concerns about rich current multiples. The company's valuation hinges heavily on the success of its Phase 3 HAELO trial and ambitious revenue growth targets.
INTELLIA THERAPEUTICS ($NTLA) Releases Q4 2025 Earnings
INTELLIA THERAPEUTICS ($NTLA) reported its Q4 2025 earnings, surpassing analyst estimates with -$0.83 per share and revenue of $23,020,000. The article also details recent insider trading activities, hedge fund movements, and current analyst ratings and price targets for the stock.
